Predictive diagnostics of lymph nodes metastatic lesion in patients with gastric adenocarcinoma
https://doi.org/10.21886/2219-8075-2018-9-1-51-62
Abstract
Objective: lymph node metastases occur in 90% of cases in patients with gastric adenocarcinoma, and survival is less than 15% in the late stages of disease. Therefore, the purpose of the study was to screening markers for predicting the likelihood of metastases developing in gastric adenocarcinoma. Materials and methods: for the study 47 patients with diagnosis of gastric adenocarcinoma were used (with the localized tumor form T3-4N0M0 (n = 18) and the locally distributed form T3-4N1-3M0 (n = 29)). The copy number variation of 16 genes (APC, AURKA, CCND1, C-MYC, GKN1, HER2, IRX1, MDM2, MET, NFKB, OCT1, P53, PIK3CA, POU5F1B, S6K2 and HV2) was determined by RT-PCR. Immunohistochemical studies were performed on sections of paraffin blocks using monoclonal antibodies to p53, Bcl-2, Ki-67 and Her2. Results: the loss of duplicity of HV2 locus was most frequent CNV in samples of stomach adenocarcinoma, but CNV significant change in the T3-4N0M0 group relative to T3-4N1-3M0 was not detected. A significant increase of CNV in the T3-4N1-3M0 group relative to T3-4N0M0 was found in 2 of 16 loci - NFKB and HER2 in 1.75 and 1.90 times (p<0.0005), respectively. Th e value of p53 expression in the tumor cells nuclei in the group without metastases was lower by 52% compared to the expression in the metastatic group (p<0.05). Low proliferative activity prevailed in the group without metastases in contrast to the group with metastases, in which Her2 overexpression was also observed in 43% of cases in contrast to 20% of cases in the group without metastases. Conclusions: it was showed that the relative copies number of NFKB1 and HER2 in combination with the immunohistochemical parameters of Ki67 and HER2 in gastric tumors can be a prognostic marker of metastasis, and algorithm for predicting metastases development in gastric adenocarcinoma is formed on basis of this.
About the Authors
O. I. KitRussian Federation
corresponding member. RAS, Doctor of Medicine, Professor, General Director
D. S. Kutilin
Russian Federation
Ph.D. Laboratory of Molecular Oncology, Rostov Research Institute of Oncology
M. Z. Tatimov
Russian Federation
post-graduate student
A. A. Maslov
Russian Federation
MD, Professor, Chief Physician
E. M. Frantsiyants
Russian Federation
Doctor of Biological Sciences, Professor, Deputy Director General for Science
D. I. Vodolazhsky
Russian Federation
Ph.D., Head of the Laboratory of Molecular Oncology
References
1. Wang X, Liu Y, Shao D, Qian Z, Dong Z, Sun Y et al. Recurrent amplifi cation of MYC and TNFRSF11B in 8q24 is associated with poor survival in patients with gastric cancer. Gastric Cancer. 2016;19(1):116-27. doi: 10.1007/s10120-015-0467-2.
2. Kaprin AD, Starinskii VV, Petrova GV. Zlokachestvennye novoobrazovaniya v Rossii v 2015 godu (zabolevaemost’ i smertnost’). Moskva, 2017. (in Russ.)
3. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric Adenocarcinoma: Review and Considerations for Future Directions. Annals of Surgery. 2005;241(1):27-39. doi:10.1097/01.sla.0000149300.28588.23
4. Takuji G, Yanagisawa A, Sasako M, Ono H, Nakanishi Y, Shimoda T, Kato Y. Incidence in lymph node metastasis from early gastric cancer: estimation with a large number of cases at two large centers. Gastric Cancer. 2000;3:219-225.
5. Kit OI, Vodolazhskii DI, Kutilin DS, Gudueva EN. Changes in the copy number of genetic loci in gastric cancer. Molekulyarnaya biologiya. 2015;49(4):658-666. (in Russ.) DOI: 10.7868/S0026898415040096
6. Kit OI, Vodolazhskii DI, Kutilin DS, Tatimov MZ, Gudueva EN, Maslov AA. Copy number variation of genetic loci – a predictive marker of metastasis in stomach cancer patients. Sovremennye problemy nauki i obrazovaniya. 2015;6. Available from: https://science-education.ru/ru/article/view?id=22967 (Accessed on December 14, 2017) (in Russ.)
7. Andrews J, Kennette W, Pilon J, Hodgson A, Tuck AB, Chambers AF, Rodenhiser DI. Multi-Platform Whole-Genome Microarray Analyses Refi ne the Epigenetic Signature of Breast Cancer Metastasis with Gene Expression and Copy Number. PLoS One. 2010;5(1):e8665. doi: 10.1371/journal. pone.0008665
8. Kim S, Lee J, Hong ME, Do I.-G., Kang SY., Ha SY et al. High-Th roughput Sequencing and Copy Number Variation Detection Using Formalin Fixed Embedded Tissue in Metastatic Gastric Cancer. PLoS One. 2014; 9(11): e111693. doi: 10.1371/journal.pone.0111693.
9. Liang L, Fang J-Y, Xu J. Gastric cancer and gene copy number variation: emerging cancer drivers for targeted therapy. Oncogene. 2016;35(12):1475-82. doi: 10.1038/onc.2015.209
10. Deng N, Goh LK, Wang H, Das K, Tao J, Tan IB et al. A comprehensive survey of genomic alterations in gastric cancer reveals systematic patterns of molecular exclusivity and co-occurrence among distinct therapeutic targets. Gut. 2012;61(5):673-84. doi: 10.1136/gutjnl-2011-301839
11. Harari D, Yarden Y. Molecular mechanisms underlying ErbB2/ HER2 action in breast cancer. Oncogene. 2000;19(53):6102-14. DOI: 10.1038/sj.onc.1203973
12. 12. McCormick Matthews LH, Noble F, Tod J, Jaynes E, Harris S, Primrose JN et al. Systematic review and meta-analysis of immunohistochemical prognostic biomarkers in resected oesophageal adenocarcinoma. Br J Cancer. 2015;113(1):107-18. doi: 10.1038/bjc.2015.179
13. Tan C, Qian X, Guan Z, Yang B, Ge Y, Wang F, Cai J. Potential biomarkers for esophageal cancer. Springerplus. 2016;5:467. doi: 10.1186/s40064-016-2119-3
14. Song Y, Huang J, Wang JW. Relationship between HER2/neu gene amplifi cation and protein expression and prognosis in patients with advanced gastric carcinoma. Chin J Cancer. 2010;29(1):76-81.
15. Zhang XL, Yang YS, Xu DP, Qu JH, Guo MZ, Gong Y, Huang J. Comparative study on overexpression of HER2/neu and HER3 in gastric cancer. World J Surg. 2009;33(10):2112-8. doi: 10.1007/s00268-009-0142-z.
16. 16. Sittel C, Ruiz S, Kvasnicka HM, Volling P, Jungehülsing M, Eckel HE. Prognostic relevance of proliferation marker Ki-67 (MIB 1), PCNA and p53 in combined surgically and radiologically treated cancers of the oropharynx and mouth cavity. Laryngo-rhino-otologie. 2000;79(2):86-92. DOI: 10.1055/s-2000-8788
17. Petrov SV, Raikhlin NT. Rukovodstvo po immunogistokhimicheskoi diagnostike opukholei cheloveka. Kazan’: Tatmedia, 2012. (in Russ.)
18. Staudt LM. Oncogenic activation of NF-kappaB. Cold Spring Harb Perspect Biol. 2010;2(6):a000109. doi: 10.1101/ cshperspect.a000109.
19. Kornienko IV, Vodolazhskii DI, Veiko VP, Shcherbakov VV, Ivanov PL. Podgotovka biologicheskogo materiala dlya molekulyarno-geneticheskikh identifi katsionnykh issledovanii pri massovom postuplenii neopoznannykh tel. Rostovna-Donu: OOO «Rostizdat», 2001. (in Russ.)20. Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;(25):402-408. DOI: 10.1006/ meth.2001.1262
20. Fang Z, Xiong Y, Li J, Liu L, Zhang W, Zhang C et al. APC gene deletions in gastric adenocarcinomas in a Chinese population: a correlation with tumour progression. Clin Transl Oncol. 2012;14(1):60-65. doi: 10.1007/s12094-012-0762-x
21. Tsai PC, Huang SW, Tsai HL, Ma CJ, Hou MF, Yang LP et al. Th e association between DNA copy number aberrations at chromosome 5q22 and gastric cancer. PLoS One. 2014;9(9):e106624. doi: 10.1371/journal.pone.0106624
22. Scatena R. Mitochondria and cancer: a growing role in apoptosis, cancer cell metabolism and dediff erentiation. Adv Exp Med Biol. 2012;942:287-308. doi: 10.1007/978-94-007-2869-1_13
23. Sonoda A, Mukaisho K, Nakayama T, Diem VT, Hattori T, Andoh A et al. Genetic lineages of undiff erentiated-type gastric carcinomas analysed by unsupervised clustering of genomic DNA microarray data. BMC Med Genomics. 2013;6:25. doi: 10.1186/1755-8794-6-25
24. Hayashi H, Arao T, Togashi Y, Kato H, Fujita Y, De Velasco MA et al. Th e OCT4 pseudogene POU5F1B is amplifi ed and promotes an aggressive phenotype in gastric cancer. Oncogene. 2015;34(2):199-208. doi: 10.1038/onc.2013.547
25. Wu C-S, Chen M-F, Lee I-L, Tung S-Y. Predictive Role of Nuclear Factor-κB Activity in Gastric Cancer: A Promising Adjuvant Approach WithCaff eic Acid Phenethyl Ester. Journal of Clinical Gastroenterology. 2007;41(10):894-900. DOI: 10.1097/MCG.0b013e31804c707c
26. Chia N-Y, Tan P. Molecular classifi cation of gastric cancer. Ann Oncol. 2016;27(5):763-769. doi: 10.1093/annonc/ mdw040
27. Chumakov PM. Belok p53 i ego universal’nye funktsii v mnogokletochnom organizme. Uspekhi biologicheskoi khimii. 2007;(47):3-52. (in Russ.)
28. Raikhlin NT, Raikhlin AN. Regulyatsiya apoptoza v fi ziologicheskikh usloviyakh i v opukholyakh. Voprosy onkologii. 2002;48(2):159-71. (in Russ.)
Review
For citations:
Kit O.I., Kutilin D.S., Tatimov M.Z., Maslov A.A., Frantsiyants E.M., Vodolazhsky D.I. Predictive diagnostics of lymph nodes metastatic lesion in patients with gastric adenocarcinoma. Medical Herald of the South of Russia. 2018;9(1):51-62. (In Russ.) https://doi.org/10.21886/2219-8075-2018-9-1-51-62